Institutional Core Labs
- iLabs
- Bioanalytics & Single-Cell
- Biospecimen and Translational Genomics
- Flow Cytometry
- Mass Spectometry
- Optical Imaging
- Structural Biology (NMR)
- Structural Biology (X-Ray Crystallography)
Find a Researcher
Research by School
Software Training & Cyberinfrastructure
Additional Resources
- Environmental Health & Safety
- Council of Principal Investigators
- National Academy of Inventors
- Office of Technology Commercialization
- Postdoc Positions
- Report A Discovery
- Research Directory
- San Antonio Bioscience Research
- San Antonio Partnership for Precision Therapeutics
- Spotlight on Research Integrity
Infectious Disease
UT Health San Antonio examines infectious diseases of regional and national significance, including hepatitis, HIV, multidrug resistant bacteria, clostridium difficile and MRSA infections.
Infectious disease expert Sunil Ahuja, M.D. earned the prestigious MERIT Award an honor bestowed on less than five percent of NIH-funded researchers.
Dr. Thomas Patterson led one of the largest study sites for the remdesivir COVID-19 clinical trial in the world.
Join us in the fight against COVID-19! The Novavax clinical trial to evaluate an investigational vaccine is enrolling participants. Take action today...volunteer and play a role in finding a cure.
Find
UT Health San Antonio partners with the Vaccine Development Center of San Antonio which fosters research collaborations to promote excellence in vaccine development.
Additional Highlights
-
Study validates shorter treatment for major world infection, tuberculosis
Four months of multi-drug therapy that included rifapentine and moxifloxacin treated active tuberculosis (TB) as effectively as the standard six-month regimen in a multinational study, cutting treatment time by a third. Coauthors including Marc Weiner, MD, of The University of Texas Health Science Center at San Antonio, reported the findings May 6 in the New England Journal of Medicine.
Read the full story in newsroom -
Novavax vaccine is highly protective against COVID-19 in Phase 3 results
Researchers at UT Health San Antonio are buoyed by today’s news that the Novavax vaccine is strongly effective against the COVID-19 virus. Biotechnology company Novavax released Phase 3 clinical trial results from 119 sites in the U.S. and Mexico this morning (June 14).
Read the full story on newsroom -
HIV research yields potential drug target
Humans possess a formidable multi-layered defense system that protects us against viral infections. Better understanding of these defenses and the tricks that viruses use to evade them could open novel avenues for treating viral infections and possibly other diseases.
Read the full story in the Newsroom -
KENS 5: Coronavirus and its potential effect on those with HIV
Dr. Waridibo Allison, Infectious Diseases/medical director, San Antonio AIDS Foundation Clinic, was featured on KENS 5 discussing HIV and COVID-19.
Read the article at UT Health San Antonio's Newsroom